PDL BioPharma Inc. (NASDAQ: PDLI) has now shown where its next revenue stream will be coming from. The company announced on Tuesday that it has committed to an equity investment in Noden Pharma DAC.…
Selecta Biosciences has filed its paperwork with the Securities and Exchange Commission to conduct an initial public offering (IPO) ahead. The company applied to list its common stock on The Nasdaq Global Market under…
Nant Health expects to price more than 6 million shares in the range of $12.50 to $15.50 for an initial public offering valued up to more than $115 million.
Leerink issued a report telegraphing that health insurance mergers might be more at risk and that one is more likely to close.
Nanosphere started the week off with a bang on Monday, following an update on an acquisition offer.
Biotech is the one arena that still offers massive upside for investors — if they can pick the right companies that is. They could one day cure cancer, heart issues, diabetes and just about…
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these abstracts.
Tonix Pharmaceuticals watched its shares take a handy jump early on Thursday, following positive results from its mid-stage PTSD study.
Cotiviti expects to price more than 12 million shares in the range of $17 to $19 per share in an initial public offering valued up to more than $273 million.
Editas Medicine Inc. (NASDAQ: EDIT) has become a rather interesting stock for many speculative biotech and biohealth investors. It has also been quite volatile. Its shares were trading higher on Monday after the release of…
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Three solid health care ideas featured by RBC are posting good numbers and expanding their product silos in an effort to continue to add new business.
Valeant Pharmaceuticals is trying to change its tune by announcing that it will offer an enhanced rebate program to all hospitals in the United States, in an effort to reduce the price of Nitropress…
Aduro BioTech has announced that the Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior…
Pfizer has announced that it has reached a definitive agreement to acquire Anacor Pharmaceuticals in a deal valued at more than $5 billion.
